ArticlesClinical assessment incorporating a personal genome
Introduction
Technological advance has greatly reduced the cost of genetic information. However, the explanatory power and path to clinical translation of risk estimates for common variants reported in genome-wide association studies remain unclear. Much of the reason lies in the presence of rare and structural genetic variation. Since we are now able to rapidly and inexpensively sequence complete genomes,1, 2, 3, 4, 5 comprehensive genetic risk assessment and individualisation of treatment might be possible.6 However, present analytical methods are insufficient to make genetic data accessible in a clinical context, and the clinical usefulness of these data for individual patients has not been formally assessed. We aimed to undertake an integrated analysis of a complete human genome in a clinical context.
Section snippets
Patient
A patient with a family history of vascular disease and early sudden death was assessed at Stanford's Center for Inherited Cardiovascular Disease by a cardiologist (EAA) and a board-certified genetic counsellor (KEO). We took the patient's medical history and he was clinically assessed. A four-generation pedigree was drawn. In view of his family history, he underwent electrocardiography, an echocardiogram, and a cardiopulmonary exercise test.
Genome analysis
Technical details of genome sequencing for this
Results
The patient was a 40-year-old man who presented with a family history of coronary artery disease and sudden death. His medical history was not clinically significant and the patient exercised regularly without symptoms. He was taking no prescribed medications and appeared well. Clinical characteristics were within normal limits (table 1). Electrocardiography showed sinus rhythm, normal axis, and high praecordial voltage with early repolarisation. An echocardiogram revealed normal right and left
Discussion
We provide an approach to comprehensive analysis of a human genome in a defined clinical context. We assessed whole-genome genetic risk, focusing on variants in genes that are associated with mendelian disease, novel and rare variants across the genome, and variants of pharmacogenomic importance. Additionally, we developed an approach to the integration of disease risk across several common polymorphisms. Although the methods that we used are nascent, the results provide proof of principle that
References (54)
- et al.
Massively parallel sequencing: the next big thing in genetic medicine
Am J Hum Genet
(2009) - et al.
Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy
Atherosclerosis
(2009) - et al.
A homozygous nonsense mutation in the beta 3 chain gene of laminin 5 (LAMB3) in Herlitz junctional epidermolysis bullosa
Genomics
(1994) - et al.
Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations
J Am Coll Cardiol
(2001) - et al.
Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden
J Mol Cell Cardiol
(2003) - et al.
Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy
J Am Coll Cardiol
(2004) - et al.
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene
Am J Hum Genet
(2008) - et al.
Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy
Blood
(2009) - et al.
CYP4F2 genetic variant alters required warfarin dose
Blood
(2008) - et al.
Genetic diagnosis by whole exome capture and massively parallel DNA sequencing
Proc Natl Acad Sci USA
(2009)
Targeted capture and massively parallel sequencing of 12 human exomes
Nature
The complete genome of an individual by massively parallel DNA sequencing
Nature
A highly annotated whole-genome sequence of a Korean individual
Nature
The diploid genome sequence of an individual human
PLoS Biol
Single-molecule sequencing of an individual human genome
Nat Biotechnol
SIFT: predicting amino acid changes that affect protein function
Nucleic Acids Res
The human gene mutation database: 2008 update
Genome Med
Human non-synonymous SNPs: server and survey
Nucleic Acids Res
Mitochondrial genome single nucleotide polymorphisms and their phenotypes in the Japanese
Ann N Y Acad Sci
The Universal Protein Resource (UniProt) 2009
Nucleic Acids Res
PolyDoms: a whole genome database for the identification of non-synonymous coding SNPs with the potential to impact disease
Nucleic Acids Res
Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base
Pharmacogenomics J
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease
Arterioscler Thromb Vasc Biol
Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand
Arthritis Rheum
Iron-overload-related disease in HFE hereditary hemochromatosis
N Engl J Med
Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis
Proc Natl Acad Sci USA
Mutations in BTD causing biotinidase deficiency
Hum Mutat
Cited by (596)
Genomics and its role in crop improvement
2022, Bioinformatics in Agriculture: Next Generation Sequencing EraSystem biology
2022, Metabolomics Perspectives: From Theory to Practical ApplicationScientific evidence and sources of knowledge for pharmacogenomics
2022, Clinical Decision Support for Pharmacogenomic Precision Medicine: Foundations and ImplementationDeep learning evaluation of biomarkers from echocardiogram videos
2021, EBioMedicineCitation Excerpt :The ability to identify patients with abnormal biomarkers has important implications for disease screening and patient management. Diagnostic medical testing provides insight into human physiology and disease conditions, with testing ranging from blood based biomarkers and genetics testing to imaging studies that provide deep insight into anatomy and changes over time [1–3]. Blood based laboratory testing is a fundamental tool for disease diagnosis and management as changes in assayable biomarkers can be some of the earliest signs of physiological perturbations [5–7].
Approaches to the comprehensive interpretation of genome-scale sequencing
2021, Clinical DNA Variant Interpretation: Theory and Practice: A Volume in Translational and Applied GenomicsImmunoblot Analysis from Single Cells Using Milo™ Single-Cell Western Platform
2024, Methods in Molecular Biology